



Summary Conflict of Interest Statements SGBCC 2023

Last name	First name	CoI Yes/No:	Statement
Aebi	Stefan	Yes, I need to declare a conflict of interest	Participation in advisory boards of AstraZeneca, , Gilead, MSD; Novartis, Pfizer, Seagen.
Al-Foheidi	Meteb	No, I do not need to declare a conflict of interest	
Anderson	Benjamin	No, I do not need to declare a conflict of interest	
André	Fabrice	No, I do not need to declare a conflict of interest	
Anikusko	Mikola	No, I do not need to declare a conflict of interest	
Badwe	Rajendra	No, I do not need to declare a conflict of interest	
Barrio	Andrea V.	No, I do not need to declare a conflict of interest	
Barrios	Carlos	Yes, I need to declare a conflict of interest	Grants/research support: (to the institution) Abbvie, Nektar, Pfizer, Polyphor, Amgen, Daiichi Sankyo, Sanofi, Exelixis, Regeneron, Novartis, Henlius, Shanghai, GSK, Janssen, OBI Pharma, Lilly, Seagen, Checkpoint Therapeutics, Roche, BMS, MSD, Merck Serono, Astra Zeneca, Novocure, Aveo Oncology, Takeda, TRIO, PharmaMar, Celgene, Myovant, PPD, Syneos Health, Docs, Labcorp, ICON, IQVIA, Parexel, Nuvisan, PSI, Medpace Academic Research Projects: CPO, PUCRS, LACOG, GBECAM. Ownership or Stocks: Tummi, MEDSir Advisory Boards and Consulting: Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Bayer, MSD, Astra Zeneca, Zodiac, Lilly, Sanofi, Daiichi
Bergh	Jonas	Yes, I need to declare a conflict of interest	Research grants from Amgen, AstraZeneca, Bayer, Merck, Pfizer, Roche, and Sanofi-Aventis to Karolinska Institutet and/or University Hospital. No personal payments. Co-author on a chapter on "Prognostic and Predictive factors in early, non-metastatic breast cancer" in UpToDate. Honoraria to Asklepios Medicin HB. Stocks in Stratipath AB, being involved in AI based diagnostics for breast cancer. Chairperson for Coronis and Asklepios Cancer Research AB. Honoraria from Roche and AstraZeneca for chairmanship and lectures at scientific meetings and consultations for Stratipath AB.
Bonnefoi	Hervé	Yes, I need to declare a conflict of interest	Advisory: AZ-Daiichi; travel grants: Pfizer; AZ-Daiichi
Bretel Morales	Denisse	No, I do not need to declare a conflict of interest	



Summary Conflict of Interest Statements SGBCC 2023

Last name	First name	CoI Yes/No:	Statement
Brucker	Sara	Yes, I need to declare a conflict of interest	Advisory Boards/Lecures for Roche, Pfizer, AZ
Burstein	Harold J.	No, I do not need to declare a conflict of interest	
Caldas	Carlos	No, I do not need to declare a conflict of interest	
Cameron	David	No, I do not need to declare a conflict of interest	
Cardoso	Fatima	Yes, I need to declare a conflict of interest	Financial disclosures: Personal financial interest in form of consultancy role for: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, Macrogenics, Medscape, Merck Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, Touchime.
Cardoso	Maria-Joao	No, I do not need to declare a conflict of interest	
Carey	Lisa	No, I do not need to declare a conflict of interest	
Chia	Stephen	Yes, I need to declare a conflict of interest	Received honorarium: Novartis, Hoffmann LaRoche, Pfizer, Eli Lilly, AstraZeneca, Amgen, Gilead, Merck, and Exact Sciences Received research grants (to the BCCA): Novartis, Hoffmann LaRoche, Pfizer, Genomic Health (Exact Sciences), AstraZeneca, Genentech, Celgene, Amgen, BMS, Merck, Sanofi, PUMA, Gilead
Coles	Charlotte	No, I do not need to declare a conflict of interest	
Connolly	Roisin	Yes, I need to declare a conflict of interest	RC has received an unrestricted educational grant from Pfizer, and research funding for clinical trials from MSD Ireland, Pfizer, Daichii Sankyo, and Astra Zeneca; all to her institution. RC has consulted for Astra Zeneca/Daichii, Gilead (and Seagen. She has received travel support from Novartis



Summary Conflict of Interest Statements SGBCC 2023

Last name	First name	CoI Yes/No:	Statement
Cortes	Javier	Yes, I need to declare a conflict of interest	<p>Consulting/Advisor: Roche , Celgene, Cellectia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, HiberCell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics. Honoraria: Roche , Novartis , Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme, Daiichi Sankyo.</p> <p>Research funding to the Institution: Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piquor Therapeutics, Puma C, Queen Mary University of London.</p> <p>Stock: MedSIR, Nektar Pharmaceuticals, Leuko (relative) Travel, accommodation, expenses: Roche, Novartis, Eisai, pfizer, Daiichi Sankyo, Astrazeneca, Gilead. Patents: Pharmaceutical Combinations of A PI3k Inhibitor And A Microtubule Destabilizing Agent.Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A. Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/0338368 A1</p>



Summary Conflict of Interest Statements SGBCC 2023

Last name	First name	CoI Yes/No:	Statement
Curigliano	Giuseppe	Yes, I need to declare a conflict of interest	Giuseppe CURIGLIANO report Honoraria for speaker's engagement: Roche, Seattle Genetics, Novartis, Lilly, Pfizer, Foundation Medicine, NanoString, Samsung, Celltrion, BMS, MSD; Honoraria for providing consultancy: Roche, Seattle Genetics, NanoString; Honoraria for participating in Advisory Board: Roche, Lilly, Pfizer, Foundation Medicine, Samsung, Celltrion, Mylan; Honoraria for writing engagement: Novartis, BMS; Honoraria for participation in Ellipsis Scientific Affairs Group; Institutional research funding for conducting phase I and II clinical trials: Pfizer, Roche, Novartis, Sanofi, Celgene, Servier, Orion, AstraZeneca, Seattle Genetics, AbbVie, Tesaro, BMS, Merck Serono, Merck Sharp Dome, Janssen-Cilag, Philogen, Bayer, Medivation, Medimmune.
de Boniface	Jana	No, I do not need to declare a conflict of interest	
De Michele	Angela	Yes, I need to declare a conflict of interest	Inivata, Novartis, Pfizer, Genentech, Calthera
De Vries	Elisabeth G E	Yes, I need to declare a conflict of interest	Institutional Financial Support for advisory boards / consultancy: Daiichi Sankyo, NSABP and Crescendo Biologics Institutional Financial Support for clinical trials or contracted research: Amgen, Genentech, Roche, Synthron, Bayer, Servier, G1 Therapeutics, Regeneron, GE Healthcare, AstraZeneca
Delaloge	Suzette	Yes, I need to declare a conflict of interest	SD reports grants and non-financial support from Pfizer, grants from Novartis, grants and non-financial support from AstraZeneca, grants from Roche Genentech, grants from Lilly, grants from Orion, grants from Amgen, grants from Sanofi, grants from Genomic Health, grants from Servier, grants from MSD, grants from BMS, grants from Pierre Fabre, grants from Exact Sciences, grants from Besins, grants from European Commission, grants from French government, grants from Fondation ARC s, grants from Taiho, grants from Elsan, all of them in relation with clinical or translational research in the breast cancer early detection, prognostication or treatment fields, all of them to my institution



Summary Conflict of Interest Statements SGBCC 2023

Last name	First name	CoI Yes/No:	Statement
Denkert	Carsten	Yes, I need to declare a conflict of interest	<ul style="list-style-type: none"> • AstraZeneca (Consulting Fees (e.g., advisory boards)) • Daiichi Sankyo (Consulting Fees (e.g., advisory boards)) • Lilly (Consulting Fees (e.g., advisory boards)) • Molecular Health (Consulting Fees (e.g., advisory boards)) • MSD Oncology (Consulting Fees (e.g., advisory boards)) • Roche (Consulting Fees (e.g., advisory boards)) • Sividon Diagnostics (Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds)) • VMScope (Receipt of Intellectual Property Rights / Patent Holder, Royalty)
Fastner	Gerd	No, I do not need to declare a conflict of interest	
Fitzal	Florian	Yes, I need to declare a conflict of interest	Scientific and meeting support as well as Ad Boards by ROCHE, Astra Zeneca, Pfizer, Novartis, MSD
Francis	Prudence	No, I do not need to declare a conflict of interest	
Gamal	Heba	No, I do not need to declare a conflict of interest	
Gentilini	Oreste Davide	Yes, I need to declare a conflict of interest	Honoraria and advisory role: MSD, Astra-Zeneca, BD, Bayer
Gnant	Michael	Yes, I need to declare a conflict of interest	M. Gnant reports personal fees / travel support from AstraZeneca, DaiichiSankyo, EliLilly, Menarini-Stemline, MSD, Novartis, PierreFabre, Veracyte; an immediate family member is employed by Sandoz.
Gradishar	William	No, I do not need to declare a conflict of interest	
Gulluoglu	Bahadir	No, I do not need to declare a conflict of interest	
Harbeck	Nadia	Yes, I need to declare a conflict of interest	NH reports honoraria for lectures and/or consulting from AstraZeneca, Daiichi-Sankyo, Gilead, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz, Sanofi, and Seagen. She is a co-director of the West German Study Group (WSG).
Heil	Jörg	No, I do not need to declare a conflict of interest	
Huang	Chiun-Sheng Huang	No, I do not need to declare a conflict of interest	



Summary Conflict of Interest Statements SGBCC 2023

Last name	First name	CoI Yes/No:	Statement
Huober	Jens	Yes, I need to declare a conflict of interest	Research Funding: Celgene, Novartis, Hexal, Lilly Honoraria: Lilly, Novartis, Roche, Pfizer, AstraZeneca, MSD, Celgene; Eisai, Abbvie, Seagen, Gilead, Daiichi Consulting, advisory relationship: Lilly, Novartis, Roche, Pfizer, Hexal, AstraZeneca, MSD, Celgene, Abbvie, Seagen, Gilead Travel expenses: Roche, Pfizer, Novartis, Celgene, Daiichi
Jiang	Zefei	No, I do not need to declare a conflict of interest	
Kaidar-Person	Orit	No, I do not need to declare a conflict of interest	
Kok	Marleen	Yes, I need to declare a conflict of interest	Research funding from AZ, BMS, Roche
Lee	Eun-Sook	No, I do not need to declare a conflict of interest	
Loi	Sherene	Yes, I need to declare a conflict of interest	Professor Sherene Loi receives research funding to her institution from Novartis, Bristol Meyers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics, Astra Zeneca and Seattle Genetics. She has acted as consultant (not compensated) to Seattle Genetics, Novartis, Bristol Meyers Squibb, Merck, AstraZeneca, Eli Lilly, Pfizer, Gilead Therapeutics and Roche-Genentech. She has acted as consultant (paid to her institution) to Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, Astra Zeneca, Silverback Therapeutics, G1 Therapeutics, PUMA Biotechnologies, Pfizer, Gilead Therapeutics, Seattle Genetics, Daiichi Sankyo, Merck, Amunix, Tallac Therapeutics, Eli Lilly and Bristol Meyers Squibb



Summary Conflict of Interest Statements SGBCC 2023

Last name	First name	CoI Yes/No:	Statement
Loibl	Sibylle	Yes, I need to declare a conflict of interest	Dr. Loibl reports grants and other from Abbvie, other from Amgen, grants and other from AstraZeneca, other from BMS, grants and other from Celgene, grants, non-financial support and other from Daiichi-Sankyo, other from Eisgenix, other from Eisai Europe Ltd, other from GSK, grants, non-financial support and other from Immunomedics/Gilead, other from Lilly, other from Merck, grants from Molecular Health, grants, non-financial support and other from Novartis, grants, non-financial support and other from Pfizer, other from Pierre Fabre, other from Relay Therapeutics, grants, non-financial support and other from Roche, other from Sanofi, non-financial support and other from Seagen, other from Olema Pharmaceuticals, outside the submitted work; In addition, Dr. Loibl has a patent EP14153692.0 pending, a patent EP21152186.9 pending, a patent EP15702464.7 issued, a patent EP19808852.8 pending, and a patent Digital Ki67 Evaluator with royalties paid.
Martin	Miguel	No, I do not need to declare a conflict of interest	
Meattini	Icro	No, I do not need to declare a conflict of interest	
Miller	Kathy D.	Yes, I need to declare a conflict of interest	Membership on advisory committees or review panels, board membership, etc. AstraZeneca, Celcuity, Genentech, Inc., and Merck and Company, Inc.
Morrow	Monica	Yes, I need to declare a conflict of interest	Exact Sciences - Honoraria
Partridge	Ann	Yes, I need to declare a conflict of interest	Uptodate Authorship Royalties
Penault-Llorca	Frederique	Yes, I need to declare a conflict of interest	ad board honoraria travel supports AstraZeneca, BMS, EISAI, Genomic Health, GSK, Jansen, Lilly, MSD, Myriad, Nanostring, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen
Piccart	Martine	Yes, I need to declare a conflict of interest	Board Member (Scientific Board) : Oncolytics <ul style="list-style-type: none"> • Consultant (honoraria) : AstraZeneca, Camel-IDS/Precirix, Gilead, Immunomedics, Lilly, Menarini, MSD, Novartis, Pfizer, Roche-Genentech, Seattle Genetics, Immutep, Seagen, NBE Therapeutics, Frame Therapeutics • Research grants to my Institute : AstraZeneca, Immunomedics, Lilly, Menarini, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon • Speakers bureau/stock ownership : none



Summary Conflict of Interest Statements SGBCC 2023

Last name	First name	CoI Yes/No:	Statement
Pierce	Lori	Yes, I need to declare a conflict of interest	Unpaid Consultant for Exact Sciences
Poortmans	Philip	Yes, I need to declare a conflict of interest	I am medical advisor of Sordina IORT Technologies, spa
Prat	Aleix	Yes, I need to declare a conflict of interest	<p>Personal financial interests Lecture fees: Roche, Pfizer, Novartis, Amgen, BMS, Nanostring Technologies and Daiichi Sankyo.</p> <p>Advisory role/consultancy: Roche, Pfizer, Novartis, Amgen, BMS, Puma, Oncolytics Biotech, MSD, Guardan Health, Peptomyc and Lilly.</p> <p>Leadership role : Reveal Genomics, SL. Institutional financial interests Contracted research: Boehringer, Novartis, Roche, anosttring, Sysmex Europa GmbH, Medica Scientia inno. Research, SL, Celgene, Astellas and Pzifer.</p> <p>Lecture fees: Nanostring technologies Clinical trials: Boehringer, Lilly, Roche, Novartis, Amgen and Daiichi Sankyo.</p> <p>Leadership roles Executive boards: Reveal Genomics, SL and SOLTI cooperative group. Patronage committee: SOLTI Foundation and Actitud Frente al Cáncer Foundation.</p>
Regan	Meredith	Yes, I need to declare a conflict of interest	to be provided
Reis-Filho	Jorge S.	Yes, I need to declare a conflict of interest	JSRF reports a leadership (board of directors) role at Grupo Oncoclinicas, stock or other ownership interests at Repare Therapeutics and Paige.AI, and a consulting or Advisory Role at Genentech/Roche, Invicro, Ventana Medical Systems, Volition RX, Paige.AI, Goldman Sachs, Bain Capital, Novartis, Repare Therapeutics, Lilly, Saga Diagnostics and Personalis.
Rubio	Isabel	No, I do not need to declare a conflict of interest	
Rugo	Hope S.	Yes, I need to declare a conflict of interest	<p>Research Support: Pfizer, Novartis, Eli Lilly, Genentech/Roche, OBI, Merck, Gilead, Daiichi Sankyo, Seattle Genetics, Sermonix, AstraZeneca, Astellas, Veru, GSK, Taiho, AMBRX and Pionyr / Consultancy/Advisory: Puma, NAPO and Blueprint / Travel to academic Meetings: Merck, Astra Zeneca, and Gilead</p>
Rutgers	Emiel	No, I do not need to declare a conflict of interest	



Summary Conflict of Interest Statements SGBCC 2023

Last name	First name	CoI Yes/No:	Statement
Saura	Cristina	Yes, I need to declare a conflict of interest	Advisory board: AstraZéneca, Gilead, Daiichi Sankyo, Seagen Int., Eisai Europe Ltd., Phillips Health Works, Pfizer Inc, Solti, Puma Biotechnology Inc, Pierre Fabre, Roche Farma,SA, Novartis. Consultant: Lilly SAU, Pierre Fabre, AstraZéneca, Exeter Pharma LLC, AX's Consulting SARL, MediTech
Senkus	Elzbieta	Yes, I need to declare a conflict of interest	<ul style="list-style-type: none"> • honoraria: Amgen, AstraZeneca, Cancérodigest, Clinigen, Curio Science, Egis, Eli Lilly, Exact Sciences, Gilead, high5md, MSD, Novartis, Oncompass Medicine, Pfizer, Pierre Fabre, Roche, Sandoz, TLC Biopharmaceuticals • travel support: Amgen, AstraZeneca, Egis, Gilead, Novartis, Pfizer, Roche • contracted research: Amgen, AstraZeneca, Eli Lilly, Novartis, OBI Pharma, Pfizer, Roche, Samsung • stock: AstraZeneca, Eli Lilly, Pfizer
Shao	Zhiming	No, I do not need to declare a conflict of interest	
Singer	Christian	Yes, I need to declare a conflict of interest	Novartis, Roche, Gilead, Daiichi, MSD, Amgen
Spanic	Tanja	Yes, I need to declare a conflict of interest	Patients advisory board - MSD and Roche Unrestricted grants from Novartis, Pfizer, AstraZeneca, Roche
Thuerlimann	Beat	Yes, I need to declare a conflict of interest	Stock: Roche, Novartis, Merck, Alcon, Innomedica; Consultant fees Innomedica, Enzymmanagement, PageTherapeutics,
Toi	Masakazu	Yes, I need to declare a conflict of interest	advisory board membership from Athenex Oncology, Bertis, BMS, Daiichi Sankyo, Eli Lilly and companies, Kansai Medical Net, and Terumo; personal fees as an invited speaker or chair from AstraZeneca, Chugai, Daiichi Sankyo, Devicore Medical Japan, Eisai, Eli Lilly and companies, Exact Science, Kyowa-Kirin, MSD, Nippon-Kayaku, Novartis, Pfizer, Shimadzu, Taiho, Takeda, Sysmex and Yakult; institutional research grants from AFI technology, Astellas, AstraZeneca, Chugai, Daiichi Sankyo, GL Science, Kyowa-Kirin, Luxonus, Nippon-Kayaku, Pfizer, Shimadzu, Shionogi, Takeda, Sanwa Shurui and Yakult; institutional funding from Chugai, Eisai, Eli Lilly and companies, Pfizer, the Japan Breast Cancer Research Group and the Kyoto Breast Cancer Research Network



Summary Conflict of Interest Statements SGBCC 2023

Last name	First name	CoI Yes/No:	Statement
Tolaney	Sara	Yes, I need to declare a conflict of interest	Consulting or Advisory Role: Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, Odonate Therapeutics, CytomX Therapeutics, Daiichi Sankyo, Athenex, Gilead, Mersana, Certara, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Chugai Pharmaceuticals, Myovant, Zetagen, Umoja Biopharma, Menarini/Stemline, Aadi Biopharma, Bayer Research Funding: Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, NanoString Technologies, Cyclacel, Nektar, Gilead, Sanofi, Seattle Genetics
Turner	Nicholas	No, I do not need to declare a conflict of interest	
Tutt	Andrew	Yes, I need to declare a conflict of interest	
van Kruchten	Michel	No, I do not need to declare a conflict of interest	
Viale	Giuseppe	Yes, I need to declare a conflict of interest	Roche, DaiichiSankyo, AstraZeneca, MSD Oncology, Agilent
Vrancken Peeters	Marie-Jeanne	No, I do not need to declare a conflict of interest	
Watanabe	Toru	No, I do not need to declare a conflict of interest	
Weber	Walter	No, I do not need to declare a conflict of interest	
Xu	Binghe	No, I do not need to declare a conflict of interest	